Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
4.635
+0.075 (+1.64%)
Streaming Delayed Price
Updated: 11:59 AM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
New York City Conference 'Horizons: Perspectives on Psychedelics' A Who's Who Of Notable Speakers
December 03, 2021
In a welcomed throwback to the days before psychedelic use and research was considered a forbidden topic, the conference “
Via
Benzinga
Both Marijuana & Psychedelic Compounds-Based Drug Stocks Indexes Declined Sharply In November
December 01, 2021
A look at which critical stage drug stock category performed best in November and which constituents contributed to that performance.
Via
Talk Markets
Topics
Cannabis
Exposures
Cannabis
COMPASS Pathways: Positive Psilocybin Trial, High-Dose Group Improves Beyond Depression Reduction
December 01, 2021
As COMPASS Pathways (NASDAQ: CMPS) crunches more data from a recent trial investigating psilocybin therapy for treatment-resistant depression (TRD), findings show that a higher...
Via
Benzinga
Peter Thiel-Backed Psychedelic Start-Up, ATAI Life Sciences, Increases Stake In Compass Pathways
November 29, 2021
Biopharmaceutical conglomerate ATAI Life Sciences (NASDAQ:ATAI), a ...
Via
Benzinga
Were Compass Pathways' Clinical Trial Results Really That Bad?
November 28, 2021
The biotech was priced for perfection; its data wasn't.
Via
The Motley Fool
Exposures
Product Safety
10 Biggest Price Target Changes For Monday
November 22, 2021
MKM Partners cut Activision Blizzard, Inc. (NASDAQ:A...
Via
Benzinga
Better Buy: Compass Pathways vs. Jazz Pharmaceuticals
November 21, 2021
Both of these biotech stocks are innovators, but one is more likely to hit it out of the park.
Via
The Motley Fool
Psychedelic Drug Stocks Continued To Decline Last Week
November 21, 2021
The 12 constituents in our Pure-Play Psychedelic Compounds-Based Drug Stocks Index declined -5.7% last week; it's now -16.1% so far in November.
Via
Talk Markets
How One Company Says It Aims To Demonstrate the Superiority of Psilocin Over Psilocybin in Treating Mental Health Conditions
November 16, 2021
Image by Mathew Schwartz from Unsplash The following post was written and/or pu...
Via
Benzinga
Use of Ketamine for Mental Disorders Rising While New Therapies Emerge
November 17, 2021
Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion...
Via
FinancialNewsMedia
Is Now the Right Time to Buy Compass Pathways?
November 13, 2021
Positive clinical trial results for psilocybin as a depression treatment didn't have the effect on the stock price that shareholders wanted.
Via
The Motley Fool
Why Compass Pathways Stock Slumped This Week
November 12, 2021
Positive trial results weren't enough to keep the company's shares from sinking this week.
Via
The Motley Fool
Compass Pathways Phase II Results: A Disappointment For Some, An Opportunity For Others
November 11, 2021
Compass Pathways reported
Via
Talk Markets
Behind the Wall: Psychedelics Have “Absolutely Transformational” Potential
November 11, 2021
Is now the time to invest in psychedelic stocks? Dustin Robinson, founder of venture capital firm Iter Investments, says yes and explains why.
Via
InvestorPlace
Is Compass Pathways Stock a Once-in-a-Lifetime Bargain?
November 11, 2021
Investors might want to give this psychedelic stock another look.
Via
The Motley Fool
75 Biggest Movers From Yesterday
November 10, 2021
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep. Check out these big penny stock gainers and losers...
Via
Benzinga
COMPASS Pathways plc (CMPS) Q3 2021 Earnings Call Transcript
November 09, 2021
CMPS earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Why Compass Pathways Shares Are Slumping More Than 22% Tuesday
November 09, 2021
The stock dropped more than $13 on Tuesday.
Via
The Motley Fool
Compass Pathways Goes On Bad Trip, Despite 'Positive' Results From Psilocybin Trial
November 09, 2021
Shares plunged, despite a psilocybin-based drug reducing depression in a trial.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 09, 2021
Gainers Frequency Therapeutics (NASDAQ:FREQ) stock rose 10.94% to $7.51 during Tuesday's regular session. The current volume of 277.7K shares is 160.43% of Frequency...
Via
Benzinga
EXCLUSIVE: Benzinga Interviews Mind Cure CEO Kelsey Ramsden with Updates on Latest Press Release
November 09, 2021
Image by: iStock The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored conte...
Via
Benzinga
58 Stocks Moving In Monday's Mid-Day Session
November 09, 2021
Gainers Dover Motorsports, Inc. (NYSE: DVD) shares climbed 60.3% to $3.59 after Speedway Motorsports announced it will acquire the company for $3.61 per share in cash. TDH...
Via
Benzinga
Compass Pathways' Psilocybin Therapy Shows Mixed Results From Depression Trial
November 09, 2021
Compass Pathways plc (NASDAQ: CMPS) has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
November 09, 2021
Gainers Compass Pathways (NASDAQ:CMPS) shares rose 18.43% to $51.0 during Tuesday's pre-market session. The company's market cap stands at $2.1 billion. As per the...
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
Detroit Decriminalizes Psychedelics
Via
Benzinga
Exposures
Product Safety
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
November 04, 2021
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat?
Via
Talk Markets
Topics
Initial Public Offering
Exposures
Securities Market
NetworkNewsAudio – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Offers Hope on the Smoking-Cessation Horizon
November 04, 2021
Via
Investor Brand Network
This Psychedelics Unicorn's Stock Is Up 50% In One Month—Beating Bitcoin, Ethereum And Dogecoin
November 04, 2021
Shares from psychedelics unicorn Compass Pathways (NASDAQ:CMPS...
Via
Benzinga
Increasing Prevalence of Depression & Mental Health Disorders Fueling Huge Growth in Psychedelic Drugs Market
November 04, 2021
Palm Beach, FL –November 4, 2021 – FinancialNewsMedia.com News Commentary – The pace of society’s change in attitude to the use of psychedelics has been amazing. It has gone from a “Born To Be Wild”,...
Via
FinancialNewsMedia
Topics
Law Enforcement
Exposures
COVID-19
Legal
Artificial Intelligence Could Be About To Replace Your Doctor
November 02, 2021
FN Media Group Presents GlobalInvestmentDaily.com Market Commentary London – November 2, 2021 – The US health and medical insurance industry is a $1.1-trillion maze that is impossible to navigate. And...
Via
FinancialNewsMedia
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
< Previous
1
2
...
22
23
24
25
26
27
28
29
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.